$ASMB
Assembly Biosciences Inc

2012 Q3 Form 10-Q Financial Statement

#000114420412044116 Filed on August 09, 2012

View on sec.gov

Income Statement

Concept 2012 Q3 2012 Q2 2011 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.180M $1.320M $1.350M
YoY Change -37.23% -65.26% -44.21%
% of Gross Profit
Research & Development $4.188M $6.162M $17.54M
YoY Change 14.12% 98.8% 2336.11%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $4.188M $6.162M $18.89M
YoY Change -24.54% 98.8% 499.68%
Operating Profit -$5.370M -$7.478M
YoY Change 8.36%
Interest Expense $10.00K $10.00K $30.00K
YoY Change -103.85% -84.83% -100.48%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income -$5.360M -$7.470M -$18.86M
YoY Change -7.59% 7.33% 101.28%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.355M -$7.470M -$18.86M
YoY Change -7.69% 7.3% 101.27%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.069M -$2.953M -$7.544M
COMMON SHARES
Basic Shares Outstanding 12.93M shares 12.49M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q3 2012 Q2 2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.60M $28.80M $37.00M
YoY Change -55.72% 152.63% 153.42%
Cash & Equivalents $23.56M $28.84M $36.98M
Short-Term Investments
Other Short-Term Assets $100.0K $157.1K $62.13K
YoY Change 0.0% 57.09%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $23.70M $29.00M $37.04M
YoY Change -55.62% 152.18% 153.68%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $9.375K $8.218K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $0.00 $9.375K $8.218K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $23.70M $29.00M $37.04M
Total Long-Term Assets $0.00 $9.375K $8.218K
Total Assets $23.70M $29.01M $37.05M
YoY Change -55.62% 152.26% 153.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.800M $3.158M $2.342M
YoY Change 50.0% 426.31% 680.69%
Accrued Expenses $800.0K $234.0K $171.0K
YoY Change 134.0% -14.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.700M $3.392M $2.513M
YoY Change 125.0% 323.98% 47.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.700M $3.392M $2.513M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.700M $3.400M $2.500M
YoY Change 125.0% 61.9% -16.67%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $12.92K $12.41K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.00M $25.62M $34.53M
YoY Change
Total Liabilities & Shareholders Equity $23.70M $29.01M $37.05M
YoY Change -55.62% 152.26% 153.74%

Cashflow Statement

Concept 2012 Q3 2012 Q2 2011 Q4
OPERATING ACTIVITIES
Net Income -$5.355M -$7.470M -$18.86M
YoY Change -7.69% 7.3% 101.27%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$5.280M -$6.940M -$16.33M
YoY Change 29.73% 142.66% 1249.59%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.166M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 4.720M 20.00K
YoY Change -100.0% 2045.45% -99.87%
NET CHANGE
Cash From Operating Activities -5.280M -6.940M -16.33M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 0.000 4.720M 20.00K
Net Change In Cash -5.280M -2.220M -16.31M
YoY Change -112.6% -15.91% -214.06%
FREE CASH FLOW
Cash From Operating Activities -$5.280M -$6.940M -$16.33M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$5.280M -$6.940M -$16.33M
YoY Change 29.73% 142.66% 1249.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
9.85
CY2012Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12934350 shares
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11368535
CY2012Q2 us-gaap Other Assets Current
OtherAssetsCurrent
157085
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1555005 shares
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
25618502
CY2012Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2012Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12922730 shares
CY2012Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
910609 shares
CY2012Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3157838
CY2012Q2 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
83173008
CY2012Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q2 us-gaap Assets
Assets
29010340
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.79
CY2012Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29010340
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28843880
CY2012Q2 us-gaap Common Stock Value
CommonStockValue
12923
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12922730 shares
CY2012Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
234000
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3391838
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2243955 shares
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Assets Current
AssetsCurrent
29000965
CY2012Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9375
CY2012Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
108778587
CY2012Q2 vtus Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
7.66
CY2012Q2 vtus Class Of Warrant Or Right Expired In Period Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExpiredInPeriodWeightedAverageExercisePriceOfWarrantsOrRights
6.60
CY2012Q2 vtus Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePriceOfWarrantsOrRights
CY2012Q2 vtus Public Offering Net Price Per Share
PublicOfferingNetPricePerShare
11.7452
CY2012Q2 vtus Remaining Securities Available Under Shelf Registration
RemainingSecuritiesAvailableUnderShelfRegistration
95500000
CY2012Q2 vtus Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
910609 shares
CY2012Q2 vtus Future Stock Based Compensation Expense Total
FutureStockBasedCompensationExpenseTotal
3420725
CY2012Q2 vtus Future Stock Based Compensation Expense Year One
FutureStockBasedCompensationExpenseYearOne
1441037
CY2012Q2 vtus Future Stock Based Compensation Expense Year Three
FutureStockBasedCompensationExpenseYearThree
577581
CY2012Q2 vtus Future Stock Based Compensation Expense Year Two
FutureStockBasedCompensationExpenseYearTwo
1400143
CY2012Q2 vtus Future Stock Based Compensation Expense Year Four
FutureStockBasedCompensationExpenseYearFour
1964
CY2012Q2 vtus Class Of Warrant Or Right Exercisable Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights
7.66
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14571055
CY2011Q4 us-gaap Other Assets Current
OtherAssetsCurrent
62129
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
34532707
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12406406 shares
CY2011Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
956443 shares
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2342074
CY2011Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
67529084
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q4 us-gaap Assets
Assets
37045781
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.40
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37045781
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36975434
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12406406 shares
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
171000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2513074
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2046455 shares
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
12406
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Assets Current
AssetsCurrent
37037563
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8218
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
102049385
CY2011Q4 vtus Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
7.61
us-gaap Operating Income Loss
OperatingIncomeLoss
-9568364
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2420775
us-gaap Share Based Compensation
ShareBasedCompensation
1555344
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
244016
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
78192
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.35
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4666935
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11964
us-gaap Investment Income Interest
InvestmentIncomeInterest
19457
us-gaap Interest Expense Other
InterestExpenseOther
86059
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11964
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3202520
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5498020
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1219380
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
49025
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4070344
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1476379
us-gaap Depreciation
Depreciation
1752
us-gaap Interest Paid
InterestPaid
121238
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7176491 shares
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
49025
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2917358 shares
us-gaap Net Income Loss
NetIncomeLoss
-9683991
us-gaap Interest Expense
InterestExpense
135084
vtus Stock Based Compensation Expense For Services
StockBasedCompensationExpenseForServices
3240965
vtus Proceeds From Exercise Of Stock Options And Warrants
ProceedsFromExerciseOfStockOptionsAndWarrants
274984
dei Trading Symbol
TradingSymbol
VTUS
dei Entity Registrant Name
EntityRegistrantName
VENTRUS BIOSCIENCES INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Type
DocumentType
10-Q
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delawre
dei Document Period End Date
DocumentPeriodEndDate
2012-06-30
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-10-07
dei Entity Central Index Key
EntityCentralIndexKey
0001426800
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
us-gaap Operating Income Loss
OperatingIncomeLoss
-15668363
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4166494
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1540553
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0111 pure
us-gaap Share Based Compensation
ShareBasedCompensation
1540553
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.65
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
878764
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
94956
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
168240 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y274D
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13025130
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3240
us-gaap Investment Income Interest
InvestmentIncomeInterest
24439
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.11
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4166494
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3240
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8131554
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3083713
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
427817
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12584650
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4896816
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7631 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
292350
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
us-gaap Depreciation
Depreciation
2083
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12518121 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0144 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3154564 shares
us-gaap Net Income Loss
NetIncomeLoss
-15643924
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
365740 shares
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
5041953
vtus Stock Based Compensation Expense For Services
StockBasedCompensationExpenseForServices
292350
vtus Class Of Warrant Or Right Grants In Period
ClassOfWarrantOrRightGrantsInPeriod
shares
vtus Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
45834 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> <b>Use of estimates:</b></p> <p style="MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#xA0;</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#xA0;</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Significant estimates inherent in the preparation of the accompanying financial statements include the fair value of stock options and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#xA0;</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Additionally, the Company provides a valuation allowance for deferred income tax assets when it is considered more likely than not that all or a portion of such deferred income tax assets will not be realized.</p> </div>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.06
vtus Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageRemainingContractualTerm
P1Y223D
vtus Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
302505
vtus Proceeds From Exercise Of Stock Options And Warrants
ProceedsFromExerciseOfStockOptionsAndWarrants
730322
us-gaap Operating Income Loss
OperatingIncomeLoss
-69442674
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1431603
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
69339661
us-gaap Share Based Compensation
ShareBasedCompensation
7480824
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3204299
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
157085
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
28843880
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1573000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42464
us-gaap Investment Income Interest
InvestmentIncomeInterest
120492
us-gaap Interest Expense Other
InterestExpenseOther
4983572
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42464
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53463430
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17328781
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2719380
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3466010
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52113893
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
82349774
us-gaap Depreciation
Depreciation
33090
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
6001496
us-gaap Interest Paid
InterestPaid
685397
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2865758
us-gaap Net Income Loss
NetIncomeLoss
-83173008
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
11522380
us-gaap Interest Expense
InterestExpense
13850826
vtus Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
341334
vtus Stock Based Compensation Expense For Services
StockBasedCompensationExpenseForServices
4283167
vtus Warrant Issued In Connection With Convertible Notes
WarrantIssuedInConnectionWithConvertibleNotes
1166989
vtus Proceeds From Exercise Of Stock Options And Warrants
ProceedsFromExerciseOfStockOptionsAndWarrants
2169762
CY2011Q3 vtus Proceeds From Secondary Offering
ProceedsFromSecondaryOffering
47600000
CY2012Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4166000
CY2012Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
354700 shares
CY2011Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6901571
CY2011Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.97
CY2011Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5967
CY2011Q2 us-gaap Interest Expense Other
InterestExpenseOther
41395
CY2011Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3801989
CY2011Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3099582
CY2011Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7176491 shares
CY2011Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
24512
CY2011Q2 us-gaap Net Income Loss
NetIncomeLoss
-6961511
CY2011Q2 us-gaap Interest Expense
InterestExpense
65907
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7478306
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2012Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
8258
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1316382
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6161924
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12627316 shares
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-7470048

Files In Submission

Name View Source Status
0001144204-12-044116-index-headers.html Edgar Link pending
0001144204-12-044116-index.html Edgar Link pending
0001144204-12-044116.txt Edgar Link pending
0001144204-12-044116-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v319101_10q.htm Edgar Link pending
v319101_ex31-1.htm Edgar Link pending
v319101_ex31-2.htm Edgar Link pending
v319101_ex32-1.htm Edgar Link pending
v319101_ex32-2.htm Edgar Link pending
vtus-20120630.xml Edgar Link completed
vtus-20120630.xsd Edgar Link pending
vtus-20120630_cal.xml Edgar Link unprocessable
vtus-20120630_def.xml Edgar Link unprocessable
vtus-20120630_lab.xml Edgar Link unprocessable
vtus-20120630_pre.xml Edgar Link unprocessable